← Back to Clinical Trials
Recruiting Phase 4 NCT07116343

NCT07116343 Intrapleural Ropivacaine Infusion in Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07116343
Status Recruiting
Phase Phase 4
Sponsor Saint Petersburg State University, Russia
Condition Cardiac Surgery
Study Type INTERVENTIONAL
Enrollment 116 participants
Start Date 2025-10-22
Primary Completion 2027-09-25

Trial Parameters

Condition Cardiac Surgery
Sponsor Saint Petersburg State University, Russia
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 116
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-10-22
Completion 2027-09-25
Interventions
Ropivacaine0.9 % NaCl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

For many patients, a primary source of postoperative pain following cardiac surgery is the presence of pleural drains, which the surgeon places at the end of the operation and maintains for 1 to 3 days. One promising method of pain management after cardiac surgery is interpleural analgesia, particularly when traditional analgesic methods, such as systemic opioids or epidural anesthesia, may be limited due to the risk of complications. Interpleural analgesia involves the introduction of local anesthetics directly into the pleural cavity through drainage tubes placed after cardiac surgery. This method targets pain receptors in the chest area, providing effective analgesia without significant systemic effects. Several clinical studies have confirmed the safety and efficacy of intrapleural administration of anesthetics after thoracic surgery. The aim of this randomised double-blind placebo controlled study is to test the hypothesis that, in patients after cardiac surgery, the quality of recovery from anesthesia with intrapleural use of ropivacaine is superior to that with a placebo.

Eligibility Criteria

Inclusion Criteria: * Scheduled cardiac surgery using a standard median sternotomy. * Planned opening of the pleural cavities. * Age more than 18 years. * Signed informed consent to participate in the study. Exclusion Criteria: * Contraindications for ropivacaine * Redo surgery

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology